A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
Conditions: Mesothelioma; Mesotheliomas Pleural; Mesothelioma, Malignant; Mesothelioma Peritoneum; Ovarian Cancer; Ovarian Serous Adenocarcinoma; Pancreatic Cancer; Pancreatic Adenocarcinoma; Colorectal Cancer; Triple Negative Breast Cancer; TNBC – Triple-Negative Breast Cancer; Ovarian Adenocarcinoma; Pancreatic Neoplasms; Colorectal Neoplasms; Ovarian Neoplasms
Interventions: Biological: TC-510; Drug: Fludarabine; Drug: Cyclophosphamide
Sponsor: TCR2 Therapeutics
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.